JPRN-UMIN000004581尚未招募未知
Effects of eplerenone on cardiovascular and metabolic disorders in patients with primary aldosteronism - Effects of aldosterone blockade in patients with primary aldosteronism
Department of Internal Medicine, Graduate School of Medical Science, Kanazawa University0 个研究点目标入组 100 人开始时间: 2011年2月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. pregnant or lactating women 2. malignant hyperension 3. secondary hypertension except for primary aldosteronism 4. diabetes mellitus patients with unstable glycemic control whose HbA1c is more than 8%, or complicated with diabetic nephropathy more than stage 2. 5. patients whose serum triglycemide is more than 400mg/dL 6. patient who is intolerate or allergic agiansts eplerenone and amlogipine 7. patient whose renal function (estimated GFR) is less than 50mL/min. 8. patient whose serum potassium level is more than 5.0mEq/L 9. patinet who sufferd from severe hepatic injury
研究者
相似试验
进行中（未招募）
不适用
The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart Failure - N/AChronic systolic heart failureMedDRA version: 8.0Level: LLTClassification code 10008908EUCTR2005-003351-12-BEPfizer Inc.2,715
进行中（未招募）
不适用
The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart Failure - N/AEUCTR2005-003351-12-PTaboratórios Pfizer, Lda2,584
进行中（未招募）
不适用
The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart Failure - N/AChronic systolic heart failureMedDRA version: 8.0Level: LLTClassification code 10008908EUCTR2005-003351-12-IEPfizer Limited2,584
进行中（未招募）
不适用
The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart Failure - N/AEUCTR2005-003351-12-CZPfizer Ltd2,715
进行中（未招募）
不适用
The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart FailureEfecto de eplerenona versus placebo sobre la mortalidad cardiovascular y la hospitalización por insuficiencia cardiaca en sujetos con insuficiencia cardiaca sistólica crónica, clasificación NYHA IIEUCTR2005-003351-12-ESPFIZER2,584